Characteristics and research collaboration of registered systematic reviews (SRs) on treatment modalities for coronavirus disease-2019 (COVID-19) remain unclear. This study analysed research collaboration, interventions and outcome measures in registered SRs on COVID-19 treatments and pointed out the relevant problems. PROSPERO (international prospective register of systematic reviews) was searched for SRs on COVID-19 treatments as of 2 June 2020. Excel 2016 was used for descriptive analyses of the extracted data. VOSviewer 1.6.14 software was used to generate network maps for collaborations between countries and institutions. A total of 189 SRs were included, which were registered by 301 institutions from 39 countries. China (69, 36.50%) exhibited the highest output. Cooperation between countries was not close enough. As an institution, the Chengdu University of Traditional Chinese Medicine (7, 3.70%) had the highest output. There was close cooperation between institutions. Interventions included antiviral therapy (81, 42.86%), respiratory support (16, 8.47%), circulatory support (11, 5.82%), plasma therapy for convalescent patients (11, 5.82%), immunotherapy (9, 4.76%), TCM (traditional Chinese medicine) treatment (9, 4.76%), rehabilitation treatment (5, 2.65%), anti-inflammatory treatment (16, 8.47%) and other treatments (31, 16.40%). Concerning antiviral therapy (81, 42.86%), the most commonly used antiviral agents were chloroquine/hydroxychloroquine (26, 13.76%), followed by remdesivir (12, 6.35%), lobinavir/ritonavir (11, 5.82%), favipiravir (5, 2.65%), ribavirin (5, 2.65%), interferon (5, 2.65%), abiron (4, 2.12%) and abidor (4, 2.12%). The most frequently used primary and secondary outcomes were the mortality rate (92, 48.68%) and hospital stay length (48, 25.40%), respectively. The expression of the outcomes was not standardised. Many COVID-19 SRs on treatment modalities have been registered, with a low completion rate. Although there was some collaboration between countries and institutions in the currently registered SRs on treatment modalities for COVID-19 on PROSPERO, cooperation between countries should be further enhanced. More attention should be directed towards identifying deficiencies of outcome measures, and the standardisation of results should be maximised.
【저자키워드】 COVID-19, Treatment, systematic review, research collaboration, outcome measures, 【초록키워드】 coronavirus disease, antiviral therapy, coronavirus, therapy, Chloroquine, Hydroxychloroquine, Immunotherapy, Ritonavir, interferon, Remdesivir, Favipiravir, Traditional Chinese medicine, rehabilitation, Intervention, outcome, ribavirin, plasma therapy, COVID-19 treatments, coronavirus disease-2019, COVID-19 treatment, Medicine, China, Convalescent patients, International, Antiviral agents, Research, plasma, mortality rate, respiratory, cooperation, antiviral agent, university, expression, outcome measures, convalescent patient, TCM, Analysis, Respiratory Support, anti-inflammatory treatment, systematic reviews, chloroquine/hydroxychloroquine, Hospital stay, followed by, (traditional Chinese medicine, completion rate, Support, deficiency, PROSPERO, problems, deficiencies, institution, Chinese, outcome measure, Registered, secondary outcome, other treatments, Descriptive analyses, country, highest, was used, generate, analysed, exhibited, searched, other treatment, Traditional, 【제목키워드】 Registered, treatments for COVID-19,